TFS Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

TFS Capital’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-27,291	Closed	-$854K	–	763
2017 Q1	$854K	Buy	+27,291	New	+$731K	0.28%	123
2016 Q2	–	Sell	-18,871	Closed	-$288K	–	1166
2016 Q1	$288K	Buy	+18,871	New	+$246K	0.04%	660
2015 Q4	–	Sell	-64,396	Closed	-$903K	–	894
2015 Q3	$903K	Sell	64,396 -773	-1%	-$14.4K	0.09%	365
2015 Q2	$1.11M	Sell	65,169 -78,360	-55%	-$1.12M	0.11%	309
2015 Q1	$1.74M	Sell	143,529 -269,983	-65%	-$2.55M	0.17%	174
2014 Q4	$3.43M	Buy	413,512 +310,997	+303%	+$2.61M	0.33%	67
2014 Q3	$891K	Buy	+102,515	New	+$926K	0.08%	410

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

TFS Capital's SUPN Position: Q2 2017 in Review

TFS Capital sold out of Supernus Pharmaceuticals (SUPN) in Q2 2017, closing a stake of 27,291 shares — an estimated $854K sold.

TFS Capital first reported a position in SUPN in Q3 2014 and held it in 7 quarters. The position peaked at $3.43M in Q4 2014. 265 funds tracked by Wall St. Rank hold SUPN as of Q2 2017.

TFS Capital reported no remaining Supernus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
TFS Capital sold 27,291 Supernus Pharmaceuticals shares in Q2 2017, an estimated $854K.
TFS Capital first reported a position in Supernus Pharmaceuticals in Q3 2014 and held it in 7 quarters.
TFS Capital's Supernus Pharmaceuticals position peaked at $3.43M in Q4 2014.
265 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.